Although blockade of the c-kit pathway may not have a therapeutic effect on SCLC, c-kit may be a promising target for the selective delivery of therapeutic agents such as toxins and radioisotopes to c-kit positive SCLC tumor cells by means of carriers such as antibodies. Here, KIT is linked to small cell lung carcinoma.